Text or call a human:Text (808) 600-9260Call
CorporateVentureCapital.com

Medpace

Corporate venture profile

Parent MedpaceHQ Cincinnati, United States

This profile covers the startup investments made by Medpace, a healthcare company. It is based in Cincinnati, United States. It invests at the Series A stage. Sectors it names: biotech and life sciences.

Every figure links to its source

Snapshot

Investment stage: Series A to Series A
Data behind this graphic
Data behind this graphic
ItemValue
Stage rangeSeries A to Series A
SectorsBiotech and life sciences
GeographyNorth America
OfficesCincinnati, United States

Sources: S1 Business Wire: NewAmsterdam Pharma completes USD 196M (EUR 160M) Series A (2021-01-14).

Graphic 1 of 2

Investment stage: Series A to Series A

Sources: S1 Business Wire: NewAmsterdam Pharma completes USD 196M (EUR 160M) Series A (2021-01-14).

Download:Report a correction
Investments closed by outcome
Data behind this graphic
Data behind this graphic
ItemCompaniesShare
Active150%
Exited150%

Status as the firm tags it

Sources: S1 Business Wire: NewAmsterdam Pharma completes USD 196M (EUR 160M) Series A (2021-01-14).

Graphic 2 of 2

Investments closed by outcome

Sources: S1 Business Wire: NewAmsterdam Pharma completes USD 196M (EUR 160M) Series A (2021-01-14).

Download:Report a correction

Where it invests

Geography

Headquarters
Cincinnati, United States
Offices
  • Cincinnati, United States

Investment regionsS1

Key facts

FactValueStatusSource
Parent companyMedpace (NASDAQ: MEDP)Reported by Wikipedia: Medpace (headquarters)S9
Parent industryHealthcare and life sciencesReported by Wikipedia: Medpace (headquarters)S9
HeadquartersCincinnati, United StatesReported by Wikipedia: Medpace (headquarters)S9
StatusActiveSingle sourceS1
Capital sourceParent company onlySingle sourceS1
StagesSeries A (inferred from announced rounds)EstimateS1

About Medpace

ItemDetailSource
Listed asNASDAQ: MEDPS9
HeadquartersUnited StatesS9

Recent rounds

DateCompanyRoundAmountLed by the firmSource
2021-01-14NewAmsterdam PharmaSeries AUSD 196MNoS1
2014-11-10Coherus BioSciencesNot statedNot statedS2

Portfolio

Portfolio companies named in public sources: NewAmsterdam Pharma, Coherus BioSciences.S1

Companies by status on the firm's list. Status as the firm tags itS1
TagCompaniesShare
Active150%
Exited150%

Official pages

Read the firm's own pages for current information.

Sources

  1. S1Business Wire: NewAmsterdam Pharma completes USD 196M (EUR 160M) Series A (2021-01-14)Portfolio company
  2. S2Global Venturing: Coherus secures USD 85m from IPO, Medpace holds 7.8% (2014-11-10)Press
  3. S9Wikipedia: Medpace (headquarters)Third-party report

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by Medpace or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.